Drug Trial Radar · NCT05456191
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
568
Actual
Start
Nov 21, 2022
Primary completion
May 15, 2025
Study completion Jul 7, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jul 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to assess the tolerability of oral asciminib (80 mg QD) in comparison with that of the second generation (2G) Tyrosine Kinase Inhibitor (TKI) nilotinib (300 mg BID), in adult patients with newly diagnosed Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP).
Conditions
- Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Interventions
AsciminibDrug
Asciminib 80 mg QD administered under fasting conditions.
NilotinibDrug
Nilotinib 300 mg twice a day (BID) was administered under fasting conditions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis)Time frame: From date of first dose to date of treatment discontinuation due to AE, assessed after 50 events had occurred, about 2 years since first patient first visit (FPFV).
- Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Primary Analysis)Time frame: From date of first dose to date of treatment discontinuation due to AE, assessed after 67 events had occurred, about 2.5 years since first patient first visit (FPFV),
Locations
119 sites in 24 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Centers
Denver, Colorado
Illinois Cancer Care
Peoria, Illinois
Regions Hospital
Saint Paul, Minnesota
Messino Cancer Centers
Asheville, North Carolina
Oncology Hematology Care Inc
Cincinnati, Ohio
Williamette Cancer Center
Eugene, Oregon
Texas Oncology P A
Bedford, Texas
Texas Oncology PA Bedford
Bedford, Texas
Virginia Oncology Associates
Norfolk, Virginia
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
CABA, Argentina
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Pleven, Bulgaria
Novartis Investigative Site
Plovdiv, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Varna, Bulgaria
Novartis Investigative Site
London, Ontario, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Plzen Bory, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Prague, Czechia
Novartis Investigative Site
Bordeaux, France
Novartis Investigative Site
Caen, France
Novartis Investigative Site
Clermont-Ferrand, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Poitiers, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Aachen, Germany
Novartis Investigative Site
Augsburg, Germany
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.